/SPRC
SPRC Stock - SciSparc Ltd.
Healthcare|BiotechnologyNASDAQ
$1.46-3.95%
$0.06 (-3.95%) • Dec 19
49
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.70
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.61
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SPRC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.45 – $1.47
TARGET (TP)$1.68
STOP LOSS$1.34
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.24
52W High$37.59
52W Low$1.43
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.31M | $2.88M | $1.35M | $1.07M | $550,000 |
| Gross Profit | $506,000 | $2.20M | $1.02M | $1.04M | $386,000 |
| Gross Margin | 38.7% | 76.3% | 76.1% | 96.9% | 70.2% |
| Operating Income | $-7,316,000 | $-5,773,000 | $-7,380,000 | $-5,768,000 | $-3,293,000 |
| Net Income | $-6,284,000 | $-5,122,000 | $-2,592,000 | $-5,801,000 | $-3,507,000 |
| Net Margin | -481.2% | -177.9% | -192.4% | -542.7% | -637.6% |
| EPS | $-1.08 | $-12.55 | $-14.73 | $-73.28 | $0.00 |
Company Overview
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SPRCBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-1.40
Q2 2025
EPS Surprise History
Q3 21
No data
Q2 22
No data
Q3 22
No data
Q2 23
No data
Q3 23
No data
Q2 24
No data
Q3 24
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Jul 24, 2025 | — | — | — | — |
Q2 2025 | Apr 24, 2025 | — | $-1.40 | — | — |
Q3 2024 | Jul 1, 2024 | — | $-1.70 | — | — |
Q2 2024 | May 6, 2024 | — | $-0.81 | — | — |
Q3 2023 | Aug 7, 2023 | — | $-2.17 | — | — |
Q2 2023 | Apr 27, 2023 | — | $2.77 | — | — |
Q3 2022 | Jul 28, 2022 | — | $-4.68 | — | — |
Q2 2022 | Apr 4, 2022 | — | $-3.47 | — | — |
Q3 2021 | Aug 26, 2021 | — | $-3.95 | — | — |
Q2 2018 | Apr 30, 2018 | — | — | — | — |
Q4 2017 | Nov 5, 2017 | — | — | — | — |
Q4 2016 | Nov 24, 2016 | — | — | — | — |
Q1 2016 | Mar 23, 2016 | — | — | — | — |
Q4 2012 | Dec 31, 2012 | — | $-0.08 | — | — |
Q2 2012 | Jun 30, 2012 | — | $-0.08 | — | — |
Latest News
SciSparc's NeuroThera Labs To Acquire 55% Stake In Israeli Quantum Bio Data Company, Issuing Shares Equal To 40% of NeuroThera's Capital; No Financial Terms Disclosed
➖ NeutralBenzinga•Dec 2, 2025, 02:31 PM
SciSparc Signs Binding Term Sheet To Acquire Patents, Trademarks and IP Rights For Endoscopic Systems And Medical Cameras From Xylo Technologies
📈 PositiveBenzinga•Dec 1, 2025, 01:33 PM
SPRC stock has given up its prior gain. SciSparc shares were trading higher after the company signed a binding term sheet to acquire patents and IP for endoscopic systems and medical cameras.
➖ NeutralBenzinga•Nov 26, 2025, 07:46 PM
SciSparc shares are trading higher after the company signed a binding term sheet to acquire patents and IP for endoscopic systems and medical cameras.
📈 PositiveBenzinga•Nov 26, 2025, 12:51 PM
SciSparc Strikes Deal To Acquire Patents For Single-Use Reflux Treatment Device MUSE
📈 PositiveBenzinga•Nov 26, 2025, 12:43 PM
SciSparc Says NeuroThera Advances Collaboration With Clearmind Medicine By Filing Israeli Patent Application For Combination Therapy Of 5-Methoxy-2-Aminoindane And N-Acylethanolamines, Targeting Depression
📈 PositiveBenzinga•Nov 20, 2025, 11:47 AM•Also:
SciSparc Says On Sept. 16, Board Resolved To Initiate Launch Of Initiative To Advance 3D Protein Modeling Using Quantum Computing Technology
📈 PositiveBenzinga•Oct 23, 2025, 01:00 PM
SciSparc And Clearmind File US Patent For Psychedelic-Based Therapy Aiming To Curb Addiction And Binge Behaviors
📈 PositiveBenzinga•Oct 20, 2025, 11:45 AM
SciSparc to acquire Miza III stake, transfer pharma portfolio; shares surge
📈 PositiveSeeking Alpha•Oct 15, 2025, 11:16 AM
SciSparc to Acquire Controlling Stake in Miza III Ventures, SciSparc Transfers Advanced Drug Portfolio to Miza in $11.6M Deal
📈 PositiveBenzinga•Oct 15, 2025, 11:07 AM
SciSparc Terminates AutoMax Merger, Secures $6.25M Repayment Plan With Structured Interest Terms
➖ NeutralBenzinga•Oct 6, 2025, 10:43 AM
SciSparc shares are trading higher after the company announced that N2OFF stockholders voted and approved the proposed acquisition of SciSparc's majority owned subsidiary, MitoCareX Bio.
📈 PositiveBenzinga•Sep 30, 2025, 02:01 PM•Also:
SciSparc shares are trading higher after the company announced that N2OFF stockholders voted and approved the proposed acquisition of SciSparc's majority owned subsidiary, MitoCareX Bio.
📈 PositiveBenzinga•Sep 29, 2025, 08:30 PM•Also:
SciSparc's subsidiary MitoCareX approved for acquisition by N2OFF shareholders; shares up 29%
📈 PositiveSeeking Alpha•Sep 29, 2025, 08:27 PM•Also:
N2OFF Receives Shareholders Approval For Merger With SciSparc's Majority Owned Subsidiary MitoCareX
📈 PositiveBenzinga•Sep 29, 2025, 08:05 PM•Also:
SciSparc Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Sep 25, 2025, 01:45 PM
Market-Moving News for September 25th
➖ NeutralBenzinga•Sep 25, 2025, 11:24 AM•Also: ,
SciSparc shares are trading higher after the company announced plans to launch a quantum computing-enabled 3D protein modeling initiative for drug discovery.
📈 PositiveBenzinga•Sep 25, 2025, 11:07 AM•Also:
SciSparc To Launch A Quantum Computing-Enabled 3D Protein Modeling Initiative For Drug Discovery
📈 PositiveBenzinga•Sep 25, 2025, 11:07 AM
SciSparc shares are trading higher after Automax Motors filed a motion to Jerusalem District Court in connection with its merger with the company.
📈 PositiveBenzinga•Sep 17, 2025, 01:03 PM
Frequently Asked Questions about SPRC
What is SPRC's current stock price?
SciSparc Ltd. (SPRC) is currently trading at $1.46 per share. The stock has moved -3.95% today.
What is the analyst price target for SPRC?
No analyst price targets are currently available for this stock.
What sector is SciSparc Ltd. in?
SciSparc Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SPRC's market cap?
SciSparc Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does SPRC pay dividends?
No, SciSparc Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
AZTR
Azitra, Inc.
$0.29
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
ONCO
Onconetix, Inc.
$1.77
Mkt Cap: $0.0B
PTIX
Protagenic Therapeutics, Inc.
$1.19
Mkt Cap: $0.0B
SCNI
Scinai Immunotherapeutics Ltd.
$0.79
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
Explore stocks similar to SPRC for comparison